Gregory Y. H. Lip, MD - Optimising Oral Anticoagulant Use in Atrial Fibrillation: The Role of Real-World Evidence in Informing, Individualising, and Improving Care

Raffaele Califano, MD - At the Frontline in ALK+ NSCLC: Practical Approaches to TKI Therapy

Raffaele Califano, MD - At the Frontline in ALK+ NSCLC: Practical Approaches to TKI Therapy...

2 years ago

18:24

Simon Couillard, MD, MSc - Improving Outcomes in Severe Eosinophilic Asthma: Translating Recent Evidence With Biologics Into Patient Care

Simon Couillard, MD, MSc - Improving Outcomes in Severe Eosinophilic Asthma: Translating Recent Evidence With Biologics Into Patient Care...

2 years ago

26:52

Wisia Wedzicha, MD, FRCP - Taking the Evidence from Paper to Practice: Shared Perspectives on Practical Considerations in Comprehensive COPD Care

Wisia Wedzicha, MD, FRCP - Taking the Evidence from Paper to Practice: Shared Perspectives on Practical Considerations in Comprehensive COPD Care...

2 years ago

23:22

George Kassianos, CBE, MD (Hons), FRCGP / Gili Regev-Yochay, MD - Current 2024 COVID-19 Vaccination Campaign: The Evidence Supporting the Call to Action

George Kassianos, CBE, MD (Hons), FRCGP / Gili Regev-Yochay, MD - Current 2024 COVID-19 Vaccination Campaign: The Evidence Supporting the Call to Action...

2 years ago

11:04

David M. G. Halpin, MB BS, DPhil, FERS - The Case for Improved Care in COPD: Appreciating COPD as a Leading Cause of Disability and Death

David M. G. Halpin, MB BS, DPhil, FERS - The Case for Improved Care in COPD: Appreciating COPD as a Leading Cause of Disability and Death...

2 years ago

18:12

Perry Elliott, MD, FRCP - What’s New and What’s Next? Expanding Our Understanding of HCM in 2023

Perry Elliott, MD, FRCP - What’s New and What’s Next? Expanding Our Understanding of HCM in 2023...

2 years ago

24:45

Edward B. Garon, MD, MS - Abundance of Choice at First Line, Lack of Options Beyond: Addressing Unmet Needs in NSCLC Without Actionable Mutations

Edward B. Garon, MD, MS - Abundance of Choice at First Line, Lack of Options Beyond: Addressing Unmet Needs in NSCLC Without Actionable Mutations...

2 years ago

20:33

Rosalyn Juergens, MD, PhD - Why Precision Matters in NSCLC: Challenges and Solutions for Targeting Rare Oncogenic Driver Mutations in the Canadian Landscape

Rosalyn Juergens, MD, PhD - Why Precision Matters in NSCLC: Challenges and Solutions for Targeting Rare Oncogenic Driver Mutations in the Canadian Landscape...

2 years ago

15:18

Claus Vogelmeier, MD - Approaching Airway Inflammation From Another Angle: The Rationale for Targeting Type 2 Pathways in COPD

Claus Vogelmeier, MD - Approaching Airway Inflammation From Another Angle: The Rationale for Targeting Type 2 Pathways in COPD...

2 years ago

20:39

Gregory Y. H. Lip, MD - Optimising Oral Anticoagulant Use in Atrial Fibrillation: The Role of Real-World Evidence in Informing, Individualising, and Improving Care

PeerVoice Heart & Lung Video